Bleeding Risk Assessed With DOACs and Verapamil or Diltiazem; Fiber Supplements Recalled

Inbox

x

MPR Daily Dose <editor@email.empr.com> Unsubscribe

3:08 AM (20 hours ago)

to me

If you are having trouble viewing this email, click here.

MUST READS Bleeding Risk Assessed With Concomitant Direct Oral Anticoagulants and Verapamil or Diltiazem Zejula Approved for Maintenance Treatment of Advanced Ovarian Cancer Fiber Supplements Recalled Due to Possible Plastic Contamination New Dosing Schedule Approved for All Keytruda Indications Bafiertam Gets Final FDA Approval for Multiple Sclerosis COVID-19 Resource Center CME/CE Spotlight Improved Outcomes for Naïve & Heavily Treatment—Experienced HIV Patients AMA PRA Category 1 Credit(s)TM, CE for Pharmacists CLICK HERE FOR A FULL LIST OF COURSES CE/CME Powered By myCME